Guselkumab provides sustained domain-specific and comprehensive efficacy as assessed using composite endpoints in patients with active psoriatic arthritis free (Annals of the Rheumatic Diseases, 2021)

(untitled) - Coates, LC; Ritchlin, CT; Gossec, L; Helliwell, P; Rahman, P; Hsia, EC; Kollmeier, A; Xu, XL; Karyekar, C; Shawi, M; Noel, W; Jiang, Y; et al.